Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib and Acalabrutinib in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
NCT04836832Phase 1Withdrawn
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of acalabrutinib tablet (Variant 1) and duvelisib in follicular lymphoma (FL), marginal zone lymphoma (MZL) and Indolent Non-Hodgkin Lymphoma (INHL). Planned start Jul 2022; status: withdrawn.
02
Drugs
acalabrutinib tablet (Variant 1)duvelisib
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT04836832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04836832.